drugset / Trial / NCT00497679
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.
Timeline
- Start
- 2006-08
- Primary completion
- —
- Completion
- 2007-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | barasertib | Small molecule | — | Intravenous |